Latest news with #LongCOVID
Yahoo
2 days ago
- Business
- Yahoo
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments. Key Fiscal 2025 Highlights First three patients treated in Hemopurifier® cancer trial at Australian sites Indian regulatory approval received to initiate a similar oncology study Study protocol expanded to reflect evolving immunotherapy standard of care Preclinical data demonstrate 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment Collaboration with UCSF to investigate Long COVID with findings to be presented at the Keystone Symposium Operating expenses reduced significantly through streamlined operations Clinical Progress in Cancer Trial Aethlon completed Hemopurifier treatments in the first three participants enrolled in its safety, feasibility, and dose-finding study of patients with solid tumors unresponsive to anti-PD-1 agents. Participant #1 was treated at Royal Adelaide Hospital in January 2025, while Participants #2 and #3 received treatment at Royal North Shore Hospital in Sydney in June 2025. All participants completed a single 4-hour Hemopurifier treatment without device deficiencies or immediate complications and have now completed the pre-specified 7-day safety follow-up. This milestone triggers the first meeting of an independent Data Safety Monitoring Board (DSMB), to review safety data and recommend advancement to the second treatment cohort. In the next cohort, participants will receive two Hemopurifier treatments during a one-week period. Preliminary data from the first cohort, including effects on extracellular vesicle (EV) removal and anti-tumor T-cell activity, are expected in approximately three months. In parallel, the trial protocol was amended to broaden eligibility to include patients receiving combination therapies with Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®), in line with current treatment practices. Currently, only about 30% of patients receiving pembrolizumab or nivolumab experience lasting clinical responses. EVs released by tumors have been implicated in cancer progression and resistance to anti-PD-1 therapies. The Hemopurifier® is designed to bind and remove these EVs from the bloodstream, potentially improving the therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of EVs in cancer patient plasma samples. As a reminder, the primary endpoint for the approximate 9 to 18-patient study is safety. The trials will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals. Patients who do not respond to the PD-1 antibody therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to safety, the study includes exploratory analyses evaluating how many Hemopurifier® treatments are needed to decrease the concentration of EVs, and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These findings are intended to guide the design of future safety and efficacy trials, including a potential Premarket Approval (PMA) study required by the FDA and other global regulatory agencies. Regulatory Approval India On June 19, 2025, the Company received formal approval from India's Central Drugs Standard Control Organization (CDSCO) to initiate a similar trial at Medanta Medicity Hospital. The approval followed a meeting with the Subject Expert Committee and prior Ethics Committee clearance. The trial will begin following a Site Initiation Visit (SIV) conducted by Aethlon's India-based CRO, Qualtran. Preclinical Study Supports Broader Applications On May 12, 2025, the results from Aethlon's preclinical ex vivo study were published in bioRxiv, and the manuscript has been submitted to a peer-reviewed journal for publication. Those results showed that the Hemopurifier, using proprietary Galanthus nivalis agglutin (GNA) affinity resin, removed 98.5% of platelet -derived extracellular vesicles (PD-EVs) from human plasma during a timepoint equivalent to a 4-hour HP treatment. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID. The results of this study support the ongoing oncology trial in Australia and suggest potential applications of the Hemopurifier in other EV-associated diseases. The manuscript describing this study has been submitted to a peer-reviewed journal for publication. Scientific Collaboration in Long COVID Research Aethlon's collaborative research with the UCSF Long COVID Clinic was accepted for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes (August 10-13, 2025). The study analyzed blood samples from participants with Long COVID as well as controls that had recovered from COVID-19 infection to evaluate the binding of larger and smaller extracellular vesicles to the Hemopurifier's lectin affinity resin, respectively. These findings build on prior clinical evidence and support further investigation of the Hemopurifier in Long COVID, an unmet medical need affecting approximately 44 and 48 million people in the United States alone, with an estimated economic burden of 2 billion dollars in those with symptoms lasting a year. Operational Achievements In fiscal 2025, Aethlon streamlined operations and significantly reduced its operating expenses, positioning the company for sustained focus on its clinical and regulatory goals. Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025 As of March 31, 2025, Aethlon had a cash balance of approximately $5.5 million. Consolidated operating expenses for the fiscal year ended March 31, 2025, were approximately $9.3 million, representing a decrease of $3.3 million or approximately 26%, compared to $12.6 million for the fiscal year ended March 31, 2024. This reduction was primarily driven by lower payroll and related expenses, professional fees, and general and administrative costs. Payroll and related expenses declined by an approximate $1.3 million, reflecting an approximate $900,000 reduction in salaries and related expenses and an approximate $800,000 decrease in stock-based compensation. These reductions were primarily attributable to the termination of three executives—one in the fiscal year 2024, one in July and October 2024—and a workforce reduction of non-executive staff in August 2024. The decrease in stock-based compensation was primarily due to the absence of accelerated vesting charges recognized in the prior year related to the termination of our former Chief Executive Officer, as well as reduced expenses following the departure of executives and staff. These decreases were partially offset by an increase of approximately $400,000 in severance expenses associated with the termination of two former executives. Professional fees also declined by approximately $1.3 million. This decrease includes $600,000 in legal costs savings resulting from a transition to a new legal firm, and an approximate $500,000 related to the termination of services with a contract manufacturing organization and the completion of a project that involved using an outside lab to process samples. Consulting fees related to scientific projects and regulatory projects declined by approximately $300,000. These reductions were partially offset by an approximate $85,000 increase in accounting fees associated with obtaining audit firm consents for various securities filings. General and administrative expenses decreased by approximately $660,000. The reduction was driven primarily by a $534,000 reduction in costs related to fewer raw material purchases, no cleanroom certification expenses, and reduced reliance on outside services for maintenance of the manufacturing facility. Laboratory supplies and testing costs also declined by $337,000 following the completion of oncology and transplant-related projects. Insurance expenses decreased by $141,000, reflecting lower medical and workers' compensation premiums due to reduced headcount, as well as an overall decrease in business insurance costs. Additional reductions included $44,000 in travel and entertainment expenses, $24,000 decrease in office supplies, and $19,000 in depreciation expense related to the disposal of certain equipment. These decreases were partially offset by a $467,000 increase in clinical trial expenses associated with our ongoing oncology study in Australia. As a result of the above factors, our operating loss decreased to $9.3 million for the fiscal year ended March 31, 2025, from $12.6 million for the fiscal year ended March 31, 2024. Other Income (Expense) Other expenses for the year ended March 31, 2025, included a non-cash charge of approximately $4.6 million related to a warrant inducement offer. In March 2025, we offered certain warrant holders the opportunity to exercise existing warrants at a temporarily reduced exercise price in exchange for the issuance of new warrants. The inducement expense recognized represents the combined fair value of the new warrants issued and the incremental fair value resulting from the modification of the exercise price of the existing warrants. This transaction did not impact cash flows from operating activities. During the fiscal year ended March 31, 2025, we recognized approximately $324,450 in other income related to the Employee Retention Tax Credit (ERTC) under the CARES Act and subsequent legislation. We recorded the ERTC as other income in the periods in which the payments were received. In addition, we recognized $36,339 in interest income related to the ERTC during fiscal 2025. As of March 31, 2025, the remaining expected credit was recorded as a receivable within other current assets on our consolidated balance sheet. No amounts were recorded in the prior fiscal year. The consolidated balance sheets for March 31, 2025 and March 31, 2024, and the consolidated statements of operations for the fiscal years ended March 31, 2025 and 2024 follow at the end of this release. Conference Call Management will host a conference call today, Thursday, June 26, 2025, at 4:30 p.m. ET to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to Please note that registered participants will receive their dial-in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL-FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442 All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through July 26, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll-free at 1-855-669-9658. The replay conference ID number is 4903201. About Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trials in Australia and India, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ AETHLON MEDICAL, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets Unaudited ASSETS March 31, 2025March 31, 2024CURRENT ASSETS Cash and cash equivalents$ 5,501,261$ 5,441,978 Deferred offering costs-277,827 Prepaid expenses and other current assets448,539505,983 TOTAL CURRENT ASSETS5,949,8006,225,788Property and equipment, net676,2201,015,229 Operating lease right-of-use asset601,846883,054 Patents, net5501,100 Restricted cash97,81387,506 Deposits33,30533,305 TOTAL ASSETS$ 7,359,534$ 8,245,982LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIES Accounts payable$ 534,524$ 777,862 Due to related parties579,565546,434 Operating lease liability, current portion313,033290,565 Accrued professional fees472,164215,038 TOTAL CURRENT LIABILITIES1,899,2861,829,899Operating lease liability, less current portion336,718649,751 TOTAL LIABILITIES2,236,0042,479,650 STOCKHOLDERS' EQUITYCommon stock, $0.001 par value; 60,000,000 shares authorized as of March31, 2025 and 2024; 2,585,239 and 328,716 shares issued and 2,010,739 and328,716 outstanding as of March 31, 2025 and March 31, 2024, respectively2,586329 Additional paid-in capital173,092,894160,339,671 Accumulated other comprehensive loss(17,133)(6,940) Accumulated deficit(167,954,817)(154,566,728) TOTAL STOCKHOLDERS' EQUITY5,123,5305,766,332 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 7,359,534$ 8,245,982 AETHLON MEDICAL, INC. AND SUBSIDIARY Consolidated Statements of Operations and Comprehensive Loss For the fiscal years ended March 31, 2025 and 2024 Unaudited Fiscal YearFiscal Year Ended 3/31/25Ended 3/31/24OPERATING EXPENSES Professional fees$ 2,224,092$ 3,526,926 Payroll and related expenses3,874,0925,206,451 General and administrative3,243,1813,903,191 Total operating expenses9,341,36512,636,568OPERATING LOSS(9,341,365)(12,636,568)OTHER EXPENSE (INCOME), NET Interest income(298,122)(447,356) Other income(324,450)- Interest expense10,109- Other expense4,659,18818,962 Total other expense (income)4,046,725(428,394)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(13,388,090)(12,208,174)Basic and diluted net loss per share attributable to common stockholders$ (8.58)$ (38.87)Weighted average number of common shares outstanding - basic and diluted 1,560,839314,097NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(13,388,090)(12,208,174)OTHER COMPREHENSIVE INCOME/(LOSS)(10,193)(799)COMPREHENSIVE LOSS$ (13,398,283)$ (12,208,973) View original content: SOURCE Aethlon Medical, Inc.
Yahoo
4 days ago
- Health
- Yahoo
Transforming Long COVID Management: Innovative Telehealth Clinic Offers Unique Approach and Unlocks Hope for Long-Haul COVID Recovery
Struggling with post-COVID symptoms? Access expert-led telehealth support to reclaim your health—limited workshop spots available. DUNEDIN, Fla., June 24, 2025 /PRNewswire/ -- Millions of individuals suffering from long-haul COVID-19, relentless fatigue, brain fog, and shortness of breath can now access a groundbreaking telehealth solution designed to revolutionize their management and restore their quality of life. Metabolic Long COVID Consulting, a specialized telehealth clinic dedicated solely to long COVID care, is hosting a free, expert-led workshop titled "Everything You Always Wanted to Know About Long COVID, but Didn't Know Whom to Ask." This expert-led event promises to deliver cutting-edge insights and introduce a metabolic approach to reclaiming vitality, offering new pathways to recovery and improved quality of life. The workshop will be led by Boyce N. Berkel, MD, PhD, a lecturer and specialist in integrative medicine. Attendees will gain comprehensive knowledge on the latest advancements in COVID treatment, including: Medication innovations Nutrition & lifestyle interventions Combining emerging therapies tailored for COVID patients. A Metabolic and Holistic Approach to Long COVID Recovery At Metabolic Long-COVID Consulting, proper health recovery from chronic COVID symptoms goes beyond fatigue, brain fog, and gastrointestinal issues; relief starts from within. Our approach focuses on: Detoxifying the body from environmental toxins and the spike protein. Rebuilding a robust immune system Rebooting mitochondrial function for cellular energy renewal and combating Long COVID fatigue Rejuvenating the gut microbiome, Awakening your stress coping skills, and Reinforcing the five other pillars of metabolic wellness. You can monitor your measurable progress with this integrative health support through our unique symptom tracker. This personalized, step-by-step journey empowers individuals at their own pace, ensuring simplicity and success. "Our mission is to make specialized metabolic post-COVID care accessible to long-haul COVID patients worldwide," said Dr. Berkel. "With telehealth, we provide personalized solutions, support, and education that truly transform lives affected by long-haul COVID." How to Register:Participation in the telehealth workshop is "free," but registration is up at Boyce Berkel. MD, PhDFounder, Medical DirectorMetabolic Long Covid This release was issued through WebWire®. For more information, visit View original content: SOURCE Metabolic Long Covid Consulting Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Sport
- Yahoo
Jonathan Toews returns to NHL after two-year absence, signs with hometown Winnipeg Jets
After two seasons out of the NHL, former Chicago Blackhawks legend Jonathan Toews is making a comeback. Toews, who sat out the past two seasons due to health issues, signed a deal with the Winnipeg Jets on Friday, the team announced. Toews, 37, last played in the NHL during the 2022-23 season. Injuries disrupted his season, causing him to play in just 53 games. He scored a career-low 31 points. While Toews' career got off to a tremendous start, injuries disrupted his Hall of Fame performance in his prime. Toews missed the entire 2020-21 NHL season after being diagnosed with chronic inflammatory response syndrome (CIRS). He returned to action the following year, but scored just 37 points. After another tough season in 2022-23, Toews said CIRS and Long COVID were still affecting his game. Advertisement That August, Toews said he intended to sit out the 2023-24 season to focus on recovery. In March of 2025, Toews said he was ready to return to the NHL, telling The Athletic, "I still think there's something left to give.' Toews added that he wanted a fresh start, and wanted to play for a team other than the Blackhawks. It's impossible to overstate the impact Toews had on Chicago after he was selected as the No. 3 overall pick in the 2006 NHL Draft. He exceeded lofty expectations, leading the team to three Stanley Cup championships. Toews also won the 2009-10 Conn Smythe award and the Selke Trophy during the 2012-13 season for his defensive excellence. Two seasons later, he was awarded the Mark Messier leadership award. In 15 seasons with the Blackhawks, Toews registered 372 goals, 511 assists and 883 points. Those figures rank sixth, eighth and sixth — respectively — in Blackhawks history.
CTV News
20-06-2025
- Sport
- CTV News
Jonathan Toews to sign with hometown Winnipeg Jets: TSN
Chicago Blackhawks center Jonathan Toews (19) lines up for a face off during the first period of an NHL hockey game against the Buffalo Sabres, Saturday, Oct. 29, 2022, in Buffalo, N.Y. (AP Photo/Jeffrey T. Barnes, File) Jonathan Toews will be returning home to Winnipeg to play hockey. The Winnipeg-born hockey star will be signing with the Winnipeg Jets, according to TSN's Pierre LeBrun and the Winnipeg Jets. 'Hearing that Jonathan Toews has an agreement to sign with the Winnipeg Jets. The contract can't be registered until July 1,' LeBrun posted on X. 'But Toews has decided to join his hometown Jets according to league sources.' It will be a one-year deal for Toews in Winnipeg — Pierre LeBrun (@PierreVLeBrun) June 20, 2025 Toews, who has won three Stanley Cups with the Chicago Blackhawks, has not played since 2023 due to health concerns related to long COVID and chronic immune response syndrome. On Friday, the Winnipeg Jets posted on their X page an image of Toews with one message. 'The kid from St. Vital is coming home,' the post reads. This is a breaking news story. More details to come.
Yahoo
11-06-2025
- Health
- Yahoo
Still Not Feeling the Same After COVID-19? You're Not Alone
Credit - Getty Images Most people have put the COVID-19 pandemic behind them. Infections, vaccinations, or a combination of both have bolstered people's immunity, and while new variants continue to pop up, getting sick does not induce the same panic it once did. But a new study shows that recovery from COVID-19 might not be as quick or straightforward as most of us now expect. The study, published in Open Forum Infectious Diseases, found that on average, it takes many people up to three months to return to good physical health after a COVID-19 infection, and nine months to recover good mental well-being. For up to 20% of infected people who were analyzed in the study, this mental-health recovery took even longer: up to a year or more. Lauren Wisk, assistant professor in the division of general internal medicine and health services research at the David Geffen School of Medicine at University of California, Los Angeles, and her team looked at data from people who had COVID-19 at eight health facilities across the U.S. from Dec. 2020 to Aug. 2022. People were asked to fill out surveys every three months for one year about their recovery, recording physical and mental symptoms like anxiety, depression, fatigue, social participation, sleep disturbances, and pain. It took people far longer to regain their mental well-being than it did their physical health. 'To be totally honest, we didn't necessarily expect to see different recovery trajectories as big as the ones we are seeing,' says Wisk. 'While it makes sense that some people recover faster physically, and other people recover faster mentally, on average the difference that we saw was surprising.' Read More: You Could Have Long COVID and Not Even Know It Wisk and her team also asked people to self-report if they experienced Long COVID, meaning symptoms stemming from their infection that lingered for at least three months. Nearly half of people who reported both poor physical and mental qualify of life following their infections also believed they had Long COVID. While the assessment was subjective, it tracked with the data Wisk's team collected; among people who reported just poor physical health, poor mental health, or neither, there were fewer reports of Long COVID. The findings point to the need for a deeper understanding of how COVID-19 infections affect the body, physically and mentally, in the short and long term, says Wisk. 'We need to be thinking about a longer road to recovery for people, because even if someone recovers physically from their symptoms, it might not end there for them.' Appreciating these longer lasting effects could help people seek treatment for their symptoms, which may condense their recovery period. Wisk says that short courses of anxiety medications and sleep therapies, for example, could address some of the lingering effects of COVID-19. 'We know how to treat the initial infection and how to keep people alive, but we don't have a great treatment protocol for the after effects and the lingering symptoms,' says Wisk. 'These data should help to guide development of protocols in which we think of recovery over a potentially long time horizon before people get back to normal.' Contact us at letters@
